D. E. Shaw & Co., Inc. Novo Cure LTD Transaction History
D. E. Shaw & Co., Inc.
- $107 Billion
- Q3 2024
A detailed history of D. E. Shaw & Co., Inc. transactions in Novo Cure LTD stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 650,314 shares of NVCR stock, worth $17.4 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
650,314Holding current value
$17.4 Million% of portfolio
0.01%Shares
25 transactions
Others Institutions Holding NVCR
# of Institutions
262Shares Held
76.9MCall Options Held
1.17MPut Options Held
318K-
Black Rock Inc. New York, NY12.1MShares$326 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$318 Million0.0% of portfolio
-
Capital International Investors Los Angeles, CA7.92MShares$213 Million0.02% of portfolio
-
Capital World Investors Los Angeles, CA4.31MShares$116 Million0.01% of portfolio
-
Nordwand Advisors, LLC Radnor, PA3.03MShares$81.3 Million12.67% of portfolio
About NovoCure Ltd
- Ticker NVCR
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 104,950,000
- Market Cap $2.82B
- Description
- NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...